Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS)

Area of Science:

• Pulmonary Medicine
• Clinical Trials
• Biomarker Discovery

Background:

• Chronic obstructive pulmonary disease (COPD) requires better therapeutic strategies.
• Current COPD treatments lack precise patient stratification.
• Identifying reliable intermediate outcomes is crucial for drug development.

Purpose of the Study:

• To establish criteria for subclassifying COPD patients for clinical trials.
• To identify biomarkers and phenotypes predicting therapeutic benefit.
• To guide the development of targeted COPD therapies.

Main Methods:

• Multicentre observational study design.
• Enrollment of 3200 participants across four strata.
• Baseline visit, annual follow-ups, and quarterly telephone assessments.

Main Results:

• Data collection for patient stratification is ongoing.
• Biomarker and phenotype identification is in progress.
• Exacerbations and mortality are being adjudicated.

Conclusions:

• SPIROMICS will provide a framework for personalized COPD treatment.
• The study aims to accelerate the development of effective COPD therapies.
• Biomarker data will enhance the predictive power of clinical trials.